Company intelligence / Profile preview
Citius Pharmaceuticals, Inc.
Cranford, New Jersey, United Statescitiuspharma.com ↗
- Ownership
- Public · CTXR
- Development stage
- Other
01
Overview
FDA approved LYMPHIR for CTCL in August 2024; Mino-Lok completed Phase 3 trial in 2023 meeting primary and secondary endpoints; Halo-Lido completed Phase 2b trial in 2023; actively engaged with FDA for next steps on both programs
- Therapeutic areas
- GastroenterologyOncologyPulmonologyInfectious Diseases
- Modalities
- Targeted immunotherapyantibiotic solutionstopical formulationsstem cell therapy
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
University of Texas MD Anderson Cancer CenterUniversity of Pittsburgh Medical Center
04
Financials
- Market cap
- $15.3M
- Total revenue
- $0
- Enterprise value
- $5.5M
Beyond the preview
Go deeper on Citius Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Citius Pharmaceuticals, Inc..